Skip to main content
logo
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
100.72
+0.15 (0.15%)
At close: Oct 31, 2025, 4:00 PM EDT
100.82
+0.10 (0.10%)
After-hours: Oct 31, 2025, 7:59 PM EDT

Boston Scientific Revenue by Segment

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
10.01B9.50B8.90B8.35B7.80B7.32B6.97B6.71B
Cardiology Growth
28.40%29.86%27.65%24.40%20.24%15.81%13.75%13.08%
Endoscopy
2.85B2.78B2.72B2.69B2.64B2.59B2.55B2.48B
Endoscopy Growth
7.80%7.18%6.67%8.22%9.68%10.86%12.35%11.75%
Peripheral Interventions
2.70B2.60B2.49B2.41B2.30B2.23B2.18B2.11B
Peripheral Interventions Growth
17.54%16.43%14.41%14.27%11.99%12.09%12.55%11.12%
Urology
2.62B2.47B2.32B2.20B2.10B2.05B2.01B1.96B
Urology Growth
24.99%20.65%15.54%12.02%9.56%9.87%9.79%10.77%
Neuromodulation
1.17B1.14B1.12B1.11B1.08B1.04B998.00M976.00M
Neuromodulation Growth
8.47%10.14%12.22%13.22%12.45%9.28%5.83%6.32%
Specialty Pharma
------------------191.00M219.00M241.00M

Revenue by Geography

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
12.37B11.67B10.91B10.21B9.53B9.04B8.68B8.43B
United States Growth
29.81%29.15%25.71%21.19%16.25%12.49%10.49%10.40%
EMEA
3.35B3.33B3.27B3.23B3.15B3.05B2.95B2.86B
EMEA Growth
6.36%9.26%11.03%13.06%13.90%13.75%12.70%13.02%
APAC
2.98B2.86B2.74B2.69B2.62B2.54B2.50B2.40B
APAC Growth
13.76%12.38%9.56%11.83%12.75%13.47%16.50%13.52%
LACA
654.00M638.00M631.00M625.00M618.00M605.00M583.00M560.00M
LACA Growth
5.83%5.45%8.23%11.61%15.73%19.33%19.71%19.66%
Specialty Pharma
------------------191.00M219.00M241.00M

Operating Expense Breakdown

Period EndingSep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
6.67B6.49B6.22B5.98B5.75B5.43B5.34B5.19B
Selling, General, and Administrative Growth
15.91%19.44%16.45%15.30%15.62%11.66%14.20%14.82%
Research and Development
1.94B1.84B1.69B1.62B1.52B1.47B1.44B1.42B
Research and Development Growth
27.91%25.07%17.24%14.20%9.91%7.55%7.68%6.95%
Amortization
894.00M874.00M862.00M857.00M840.00M843.00M840.00M829.00M
Amortization Growth
6.43%3.68%2.62%3.38%2.44%3.56%3.96%3.24%
Asset and Goodwill Impairment
-434.00M-445.00M-459.00M--190.00M386.00M--457.00M377.00M-509.00M--
Asset and Goodwill Impairment Growth
-12.44%--2.63%-21.75%---62.67%-27.31%--4.58%-36.10%----
Litigation-related Net Charges
--------190.00M--599.00M-472.00M-448.00M-580.00M505.00M--
Litigation-related Net Charges Growth
---------67.24%--18.61%---------
Restructuring Net Charges
89.00M105.00M23.00M16.00M31.00M38.00M53.00M70.00M
Restructuring Net Charges Growth
187.10%176.32%-56.60%-77.14%-45.61%-17.39%29.27%180.00%
Royalty Expense
50.00M43.00M38.00M34.00M36.00M42.00M45.00M46.00M
Royalty Expense Growth
38.89%2.38%-15.56%-26.09%-23.40%-10.64%-2.17%-2.13%
Loss on Disposal of Assets
-----------34.00M---18.00M-----
Contingent Consideration Net Expense
10.00M-24.00M-17.00M-5.00M10.00M45.00M62.00M57.00M-
Contingent Consideration Net Expense Growth
-----150.00%77.14%62.86%-
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.